指南与共识肥胖与代谢综合征

基于人群和临床队列对代谢性高铁蛋白血症新共识定义的验证

A Population-Based and Clinical Cohort Validation of the Novel Consensus Definition of Metabolic Hyperferritinemia.
指南 / 共识 · J Clin Endocrinol Metab · 2024-01-01

本研究利用美国国家健康与营养调查(NHANES)数据库和PERSONS队列,验证代谢性高铁蛋白血症(MHF)新共识定义的临床结局。MHF定义为血清铁蛋白升高伴代谢功能障碍,按铁蛋白水平分级。在普通人群和经活检证实的代谢功能障碍相关脂肪性肝病(MAFLD)患者中,MHF均与较差的临床结局相关。

要点

  • 在NHANES中,与不伴代谢功能障碍的非MHF相比,MHF与全因死亡、尿白蛋白肌酐比值升高、心血管疾病和肌少症风险增加相关。
  • 在PERSONS队列中,MHF与更严重的脂肪变、小叶炎症、进展期纤维化和肝细胞铁沉积相关。
  • MHF的分级(特别是2/3级)与死亡风险增加相关。

核心结论

  • 在普通人群和MAFLD高危个体中,MHF均与较差的临床结局相关。

研究设计与样本

  • 研究纳入NHANES数据库和PERSONS队列,MHF定义为血清铁蛋白升高伴代谢功能障碍,并按铁蛋白水平分为1级(女性200-550 ng/mL,男性300-550 ng/mL)、2级(550-1000 ng/mL)和3级(>1000 ng/mL)。

主要发现

  • 在NHANES中,与不伴代谢功能障碍的非MHF相比,MHF与全因死亡(P < .001)、尿白蛋白肌酐比值升高(P < .001)、心血管疾病(P = .028)和肌少症(P < .001)风险增加相关。
  • 在NHANES中,与伴代谢功能障碍的非MHF相比,MHF与进展期纤维化(P = .036)、尿白蛋白肌酐比值升高(P = .001)和肌少症(P = .013)风险增加相关;所有级别MHF与死亡率的关联不显著(P = .122),但2/3级与死亡率增加相关(P = .029)。
  • 在PERSONS队列中,MHF与更高级别的脂肪变(P < .001)、小叶炎症(P < .001)、进展期纤维化(P = .017)和更严重的肝细胞铁沉积(P < .001)相关。

关键数值与推荐

  • MHF定义为血清铁蛋白升高伴代谢功能障碍,分级标准:1级为女性200-550 ng/mL、男性300-550 ng/mL;2级为550-1000 ng/mL;3级为>1000 ng/mL。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: There is limited data on the clinical significance of metabolic hyperferritinemia (MHF) based on the most recent consensus. OBJECTIVE: We aimed to validate the clinical outcomes of MHF in the general population and patients with biopsy-proven metabolic dysfunction-associated fatty liver disease (MAFLD). METHODS: The NHANES database and PERSONS cohort were included. MHF was defined as elevated serum ferritin with metabolic dysfunction (MD) and stratified into different grades according to ferritin (grade 1: 200 [females]/300 [males]-550 ng/mL; grade 2: 550-1000 ng/mL; grade 3: >1000 ng/mL). The clinical outcomes, including all-cause death, comorbidities, and liver histology, were compared between non-MHF and MHF in adjusted models. RESULTS: In NHANES, compared with non-MHF with MD, MHF was related to higher risks of advanced fibrosis (P = .036), elevated albumin-creatinine ratio (UACR, P = .001), and sarcopenia (P = .013). Although the association between all grades of MHF and mortality was insignificant (P = .122), grades 2/3 was associated with increased mortality (P = .029). When comparing with non-MHF without MD, the harmful effects of MHF were more significant in mortality (P < .001), elevated UACR (P < .001), cardiovascular disease (P = .028), and sarcopenia (P < .001). In the PERSONS cohort, MHF was associated with more advanced grades of steatosis (P < .001), lobular inflammation (P < .001), advanced fibrosis (P = .017), and more severe hepatocellular iron deposition (P < .001). CONCLUSION: Both in the general population and in at-risk individuals with MAFLD, MHF was related with poorer clinical outcomes.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Liu WY, Lian LY, Zhang H, et al. A Population-Based and Clinical Cohort Validation of the Novel Consensus Definition of Metabolic Hyperferritinemia. J Clin Endocrinol Metab. 2024. PMID: 38124275. doi:10.1210/clinem/dgad749

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。